methyl 2,4-dimethyloxazole-5-carboxylate | 1144502-57-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: methyl 2,4-dimethyloxazole-5-carboxylate
• 英文别名: methyl 2,4-dimethyl-1,3-oxazole-5-carboxylate
• CAS: 1144502-57-7
• 化学式: C₇H₉NO₃
• 分子量: 155.153
• InChiKey: TUYPRWLVDXUJQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  methyl (Z)-3-acetamido-2-butenoate 在 碘苯二乙酸 、 三氟化硼乙醚 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 0.5h， 以88%的产率得到methyl 2,4-dimethyloxazole-5-carboxylate
  参考文献：
  名称：

  Synthesis of Oxazoles from Enamides via Phenyliodine Diacetate-Mediated Intramolecular Oxidative Cyclization

  摘要：

  A group of functionalized oxazoles were synthesized in moderate to good yields from enamides via phenyliodine diacetate (PIDA)-mediated intramolecular cyclization. The main advantageous features of the present method include its broad substrate scope and the heavy-metal-free characteristic of the oxidative carbon-oxygen bond formation process.

  DOI：

  10.1021/jo302073e

文献信息

• DIAZA-BENZOFLUORANTHRENE COMPOUNDS
  申请人：HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY

  公开号：US20180016270A1

  公开（公告）日：2018-01-18

  Disclosed are a series of diaza-benzofluoranthrene compounds. The present invention particularly relates to a compound represented by formula (I), pharmaceutically acceptable salts or tautomers thereof.

  揭示了一系列二氮杂苯并芴类化合物。本发明特别涉及一种由式(I)表示的化合物，其药学上可接受的盐或互变异构体。
• AMIDE COMPOUNDS
  申请人：Kitamura Shuji

  公开号：US20120065196A1

  公开（公告）日：2012-03-15

  The present invention provides compounds represented by the formula (Ie): and the formula (If): wherein each symbol is as defined in the specification. According to the present invention, these compounds have a DGAT inhibitory activity and are useful for the prophylaxis, treatment or improvement of diseases or pathologies caused by high expression or high activation of DGAT.

  本发明提供由式(Ie)和式(If)所表示的化合物，其中每个符号如规范中所定义。根据本发明，这些化合物具有DGAT抑制活性，并可用于预防、治疗或改善由DGAT高表达或高活化引起的疾病或病理学。
• Diaza-benzofluoranthrene compounds
  申请人：HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY

  公开号：US10017507B2

  公开（公告）日：2018-07-10

  Disclosed are a series of diaza-benzofluoranthrene compounds. The present invention particularly relates to a compound represented by formula (I), pharmaceutically acceptable salts or tautomers thereof.

  本发明公开了一系列重氮苯并菲化合物。本发明尤其涉及由式（I）代表的化合物、其药学上可接受的盐或同系物。